RecruitingPhase 2NCT04980638
Intraamniotic Administrations of ER004 to Male Subjects With X-linked Hypohidrotic Ectodermal Dysplasia
Studying Ectodermal dysplasia syndrome
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- EspeRare Foundation
- Principal Investigator
- Holm Schneider, MDUniversity Erlangen-Nürnberg Erlangen, Germany
- Intervention
- ER004(biological)
- Enrollment
- 20 enrolled
- Eligibility
- 18 years · FEMALE
- Timeline
- 2022 – 2032
Study locations (8)
- Cedars-Sinai Medical Center, Los Angeles, California, United States
- Washington University, St Louis, Missouri, United States
- Hôpital Necker - Enfants Malades, Paris, Paris, France
- Universitaetsklinikum Erlangen, Erlangen, Bavaria, Germany
- Universitaetsklinikum Leipzig AoeR, Leipzig, Saxony, Germany
- IRCCS Ca' Granda Ospedale Policlinico, Milan, Italy
- Hospital Universitario Virgen de la Arrixaca, El Palmar, Murcia, Spain
- University Hospital of Wales Cardiff and Vale University Local Health, Cardiff, United Kingdom
Collaborators
Pierre Fabre Medicament · Iqvia Pty Ltd
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04980638 on ClinicalTrials.govOther trials for Ectodermal dysplasia syndrome
Additional recruiting or active studies for the same condition.